Appointments strengthen the leadership team and deepen expertise in drug discovery, oncology research, and strategic partnershipsDr. Brian Jones appointed to…
Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate…
SomaLogic’s SomaScan® platform was used to target 15 markers shared among all cancer types.BOULDER, Colo., Sept. 12, 2023 (GLOBE NEWSWIRE)…
In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild or moderate COVID-19 patients were…
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel…
Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment in non-small cell lung cancerNEW…
• Data presented at the 2023 World Conference on Lung Cancer hosted by the International Association for the Study of…
Treatment Could Help Restore Brain Functions Lost in Many Neurogenerative DisordersSAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc.,…
Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standards of care versus standards of care alone…
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) Expands Reach of Revolutionary geneType Multi-Risk Test in Australia: A major advancement towards…